Zentalis Pharmaceuticals ZNTL
NASDAQ ZNTL
$2.43 +0.04 (+1.88%)
As of: Oct 21, 2026 · 2:44 PM EDT

Zentalis Pharmaceuticals (ZNTL) EBITDA Margin (2024)

Updated

Zentalis Pharmaceuticals (ZNTL) recorded EBITDA Margin of -184.33% in Q4 2024.

Analysis

Zentalis Pharmaceuticals (ZNTL) EBITDA Margin (2024) Analysis & Trends

For FY2024, Zentalis Pharmaceuticals reported EBITDA Margin of -281.64%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.92 Bn 1,105.50 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 617.57 Bn 536.10 Bn 17.26 Bn 35.95%
3 AbbVie 501.37 Bn 474.48 Bn 12.70 Bn 49.01%
4 Merck 367.96 Bn 322.33 Bn 12.21 Bn 6.02%
5 Novartis Ag 297.98 Bn 261.97 Bn 11.24 Bn -
6 Astrazeneca 261.45 Bn 235.14 Bn 12.86 Bn 33.11%
7 Amgen 236.30 Bn 191.70 Bn 7.24 Bn 46.01%
8 Gilead Sciences 190.27 Bn 164.46 Bn 6.22 Bn -124.26%
9 Pfizer 169.65 Bn 116.29 Bn 10.94 Bn 39.16%
10 Zentalis Pharmaceuticals 173.68 Mn -736.87 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -184.33%
Mar 31, 2024 -60.26%
API Access

Zentalis Pharmaceuticals EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ZNTL&period=max&api_key=YOUR_API_KEY